A mechanistic understanding of the insurmountable antagonism of the angiotensin II type 1 (AT 1 ) receptor could be fundamental in the quest for discovery and improvement of drugs. Candesartan and EXP3174 are competitive, reversible insurmountable antagonists of the AT 1 receptor. They contain di-acidic substitutions, whereas the surmountable antagonist, losartan, contains only one acidic group. We tested the hypothesis that these two classes of ligands interact with the AT 1 receptor through similar but not identical bonds and that the differences in the acid-base group contacts are critical for insurmountable antagonism. By pharmacological characterization of site-directed AT 1 receptor mutants expressed in COS1 cells we show that specific interactions with Gln 257 in transmembrane 6 distinguishes insurmountable antagonists and that abolishing these interactions transforms insurmountable to surmountable antagonism. In the Q257A mutant, the dissociation rate of [ 3 H]candesartan is 2.8-fold more than the rate observed with wild type, and the association rate was reduced 4-fold lower than the wild type. The pattern of antagonism of angiotensin II concentration-response in the Q257A mutant pretreated with EXP3174 and candesartan is surmountable. We propose that leaning ability of insurmountable antagonists on Gln 257 in the wildtype receptor is the basis of an antagonist-mediated conformational transition, which is responsible for both slow dissociation and inhibition of maximal IP response.
1 such as the angiotensin II type 1 receptor (AT 1 ) has gained much attention, evidently due to therapeutic success of the drugs targeting this family of receptors. Antagonists of GPCRs exhibit diverse patterns of antagonism that range from the classical surmountable antagonism (parallel rightward shift of agonist concentration-response curves with no decline of the maximum response) to insurmountable antagonism (partial to complete waning of the response accompanying a seeming rightward shift of the agonist response curve). Insurmountable antagonist occupancy of the receptor generally prolongs the time taken for re-sensitization to agonist than the surmountable antagonist occupancy (1) . Common mechanisms proposed for insurmountable antagonism involve phenomena attributed to equilibrium between allosteric activity states of receptors that (i) affect the kinetics of drug-receptor interaction, (ii) induce antagonist-dependent receptor conformation that is refractory to agonist binding, and (iii) modulate coupling to unknown molecules that stabilize the antagonist-bound state of the receptor (2) (3) (4) (5) . In other instances the insurmountable antagonists forming a covalent bond with the receptor (irreversible) or the insurmountable antagonists dissociating very slowly from the receptor (pseudo-irreversible) have been proposed (2) . Even so, the molecular mechanism responsible for distinct efficacy from different types of drug-receptor complexes has remained unclear.
Pharmacological behavior of the non-peptide antagonists of the AT 1 receptor provides several advantages as a model to study insurmountable antagonism of GPCRs. AT 1 receptor antagonists displaying both types of pharmacological behavior are currently being evaluated for therapeutic potential in cardio-protective, reno-protective, anti-proliferative, and anti-fibrotic effects in addition to anti-hypertensive effects (2) (3) (4) (5) . Insurmountable antagonism is not unique to the AT 1 receptors. In fact it has been reported for GPCR systems that include those for noradrenaline, histamine, acetylcholine, 5-hydroxy tryptamine (5-HT), substance P, bradykinin, cholecystokinin, and chemotactic C5␣ receptors (2) (3) (4) (5) , suggesting that a mechanistic understanding of this important pharmacological phenomenon could be fundamental in the quest for discovery and improvement of drugs. Both classes of the AT 1 receptor antagonists share a structure with biphenyltetrazole linked to a planar substituted imidazole with a short alkyl chain (Fig. 1A) . Candesartan and EXP3174 are competitive, reversible antagonists that display insurmountable antagonism (2) (3) (4) (5) . They contain di-acidic substitutions, whereas the surmountable antagonist losartan contains only one acidic group. In aortic contraction as well as inositol phosphate (IP) production assays, preincubation with losartan produces classical surmountable antagonism, whereas candesartan and EXP3174 produce insurmountable antagonism. Co-incubation experiments and detailed kinetic analysis have lead to several proposals for the mechanism mentioned earlier (2) (3) (4) (5) .
A difference in drug-receptor-bonding interactions due to differences in the acid-base groups is one possible mechanism. We speculate that the two classes of ligands interact with the AT 1 receptor through similar but not identical bonds, and the difference in contact is critical for their pharmacological properties. In a previous study (6) we demonstrated that the tetrazole moiety of losartan interacts primarily with Lys 199 and secondarily with His 256 (see Fig. 1 ). Candesartan contains an * This work was supported by National Institutes of Health Grant HL57470 (to S. S. K.), American Heart Association Established Investigator Award (to S. S. K.) and Fellowship award (to Y. S.), and an educational grant from AstraZenecca (to S. S. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed. additional carboxylate group attached to the imidazole ring that may interact with a second positive-charged or hydrogenbonding residue in the AT 1 receptor to produce insurmountable antagonism. The ethoxy group in candesartan may form an additional hydrogen bond. Together, these differences in bonding could be the basis for insurmountable antagonism. Therefore, our goal in the present study is to identify the specific bonding interaction that distinguishes insurmountable AT 1 receptor antagonists EXP3174 and candesartan from the surmountable antagonist losartan and examine whether abolish- contains an ␣-carboxylate group, and the structure of candesartan contains ␣-carboxylate and ethoxy groups in addition to the tetrazole group. B, secondary structure model of rat AT 1 receptor, revised based on the structure of bovine rhodopsin. Candidate residues for this study are numbered. The residues Lys 199 and His 256 have previously been shown to form ion pairs with tetrazole group of losartan. The epitope tag attached at the C-terminal end for detection by the ID4 monoclonal antibody is underlined. Attachment of this sequence does not alter the properties of the AT 1 receptor.
ing the additional interaction transforms insurmountable to surmountable antagonism. of Ang II and Ang II were purchased from  Bachem (Torrance, CA [2- 3 H(N)]Inositol (1.5 Ci/ml; specific activity, 22 Ci/mol) at 37°C in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. The labeled cells were washed 2 times with Dulbecco's modified Eagle's medium and incubated in Dulbecco's modified Eagle's medium containing 10 mM LiCl for 20 min. Ang II was then added, and incubation was continued for an additional 40 min at 37°C. In the antagonist preincubation experiments, cells were preincubated with vehicle or antagonists for 30 min, Ang II was then added, and incubation was continued for another 40 min at 37°C. At the end of the incubation the medium was removed, and the total soluble IP was extracted from the cells by perchloric acid extraction, as described previously (6, 7). EC 50 and IC 50 values were calculated by non-linear regression analysis by Graphpad Prism. The values represented were mean Ϯ S.E. of at least three independent experiments performed in duplicate.
EXPERIMENTAL PROCEDURES

Materials-Analogues
TABLE I
Binding affinity of the AT 1 
wild-type and mutant receptor for peptide and non-peptide ligands
The values represented are the mean S.E. obtained from at least three independent experiments performed in duplicate. The chemical structures of the antagonists are listed in Fig. 1 . The effect of the mutations on the binding affinity is expressed as the mutation factor, Fmutant
Receptor 
Ͼ 14,000
60.4 Ϯ 6.0(75.5)
17.9 Ϯ 6.9(1.6) Molecular Modeling of the AT 1 Receptor-The molecular model used the bovine rhodopsin structure (Protein Data Bank code 1F88) as a template (8) . Using the ClustalW alignment program (Julie D. Thompson, Desmond G. Higgins, and Toby J. Gibson, European Bioinformatics Institute, Cambridge, UK), we performed the alignment of rat AT 1A receptor primary sequence with the bovine rhodopsin primary sequence. The amino acid mutations were performed by Swiss-PdbViewer (9) followed by energy minimization using the Gromacs molecular dynamics simulation program (10) . During the entire modeling process the secondary structure was monitored to ensure that the AT 1 secondary structure was conserved. This model was used for docking both the agonist and antagonist ligands, performed using AutoDock 3.0.5 program (27) . The procedure uses a Monte Carlo simulated annealing or a genetic algorithm technique for configurational exploration with rapid energy evaluation using grid-based molecular affinity potentials. , and N295A mutants. The affinity of EXP3174 was reduced in H166E, R167Q, Q257A, Q257E, and N295A mutants. However, preincubation of EXP3174 with the WT decreased the K i 4.4 times compared with no preincubation (adding the competing and tracer ligands together). A decreased K i for EXP3174 upon preincubation was observed in all mutants except the Q257A and Q257E mutants. The affinity of candesartan was reduced in H166E, R167Q, K199Q, H256A, Q257A, Q257E, and N295A mutants. A 10-fold decrease in the K i of candesartan for the WT receptor was measured upon preincubation. The preincubation-induced decrease of K i was 3-10-fold in most mutants. However, in the Q257A and Q257E mutants, the decrease of K i was 2-and 1.6-fold, respectively.
RESULTS
Candidate Residues Specific for
To unravel putative interaction between residues involved in binding the surmountable antagonist losartan and the insurmountable antagonists, EXP3174 and candesartan, three double mutants and one triple mutant of the AT 1 receptor were examined (Table I ). The combined effect of double mutations K199Q/H256A, K199Q/Q257A, and the H256A/Q257A on the K i of losartan, EXP3174, and candesartan was nearly additive in comparison to each of the single mutations. The overall effect on K i in the double mutants was nearly equal to the combined change of component single mutations. Deviation from additivity observed reflects the extent to which disruption of interaction between Lys 199 , His 256 , and Gln 257 changes measured K i . Combining all three mutations reduced the affinity Ͼ10-fold for all 3 antagonists. The affinity increase for candesartan observed upon preincubation was abolished in all four mutants. The affinity-shift for EXP3174 was also abolished in these mutants. Altogether, effects of these mutations suggest that a combinatorial interaction of residues Lys 199 , His 256 , and Gln 257 is also necessary for insurmountable binding of antagonists.
Effect of the Q257A Mutation on Losartan, EXP3174, and Candesartan Binding Kinetics- Fig. 2A depicts the effect of preincubation on competition binding of surmountable and insurmountable antagonists. Preincubation did not influence the losartan binding isotherm in the WT and the Q257A mutant. The binding isotherms for the insurmountable antagonists were shifted left in the WT. In the Q257A single mutant, the EXP3174 curve did not shift upon preincubation, and the magnitude of the candesartan curve-shift was significantly smaller compared with that in the WT AT 1 receptor. Candesartan binding isotherm-shift induced by pre-equilibration with the drug was completely abolished in the double and triple mutants (Fig. 2B) .
Direct binding experiments suggest that the dissociation of the insurmountable antagonist, candesartan, from the bound receptor was slower than the dissociation of structurally analogous surmountable antagonist, losartan. Ϫ1 , 0.595 Ϯ 0.199). The Q257A mutation affected both association and dissociation rates of candesartan (Fig. 3) (Table I) . The K i values of Q257A mutant calculated from K -1 and K 1 for both losartan (166.0 Ϯ 6.3 nM) and candesartan (68.9 Ϯ 6.2 nM) were, respectively, 10-and 4-fold higher than K i values estimated from competition binding experiment in (Table I ). This discrepancy, seen only in the Q257A mutant for both ligands, may be a reflection of a disproportionate effect of mutation on association rate than dissociation rate.
Antagonism Pattern of Ang II-induced IP Response in the WT and Q257A Mutant AT 1 Receptors-The pattern of antagonism of Ang II concentration-response in the WT and Q257A mutant suggests that display of insurmountable behavior by EXP3174 and candesartan requires the Gln 257 side chain in the WT receptor (Fig. 4) . The EC 50 value was 0.005 Ϯ 0.001 nM for the Ang II-induced IP production in the WT AT 1 receptor-transfected cells. Pre-equilibration with insurmountable antagonists for 30 min before Ang II addition caused a rightward shift in the response curves. The EC 50 values were 12.6 Ϯ 1.4 nM with 10 nM EXP3174 and 34.3 Ϯ 4.9 nM with 10 nM candesartan. The maximal response to Ang II decreased for both EXP3174 (77.7 Ϯ 4.3%) and candesartan (47.5 Ϯ 5.4%). In contrast, 100 nM losartan produced a rightward shift (EC 50 , 3.6 Ϯ 0.8 nM) but did not decrease the maximal response. In the Q257A mutant transfected cells, EXP3174 and candesartan only produced a rightward shift without altering the maximal response (see Antagonism of WT and Q257A Mutant AT 1 Receptor Activation-The activation of WT and Q257A AT 1 receptor inhibited by antagonists in a concentration-dependent manner is shown in Fig. 5 . The intrinsic basal activity of both receptors was inhibited by all three antagonists, suggesting that their inverse agonist activity is independent of insurmountable antagonist activity (Fig. 5A) . ]candesartan mixed with membranes had reached equilibrium, dissociation was induced by the addition of unlabeled 1 M candesartan. The specific binding is calculated as a percentage of the specific binding at equilibrium. Data are the mean Ϯ S.E. obtained from at least three independent experiments. The association experiments shown here were done under identical conditions. However, the association rate (K 1 ) of the antagonists derived was not useful for any interpretation because the calculated K 1 values were negative. Therefore, the association experiments were repeated for both WT and Q257A mutants with ilar maximum inhibition in both receptors.
The same pattern of antagonism was observed in Ang IIinduced activation experiments (Fig. 5B) . The order of potency of the antagonists was candesartan (IC 50 ϭ 2.9 Ϯ 0.5 versus 7.9 Ϯ 1.4 nM, respectively) Ͼ EXP3174 (IC 50 ϭ 5.0 Ϯ 1.2 versus 32.0 Ϯ 6.7 nM, respectively) Ͼ losartan (IC 50 ϭ 277.0 Ϯ 42.7 versus 545.7 Ϯ 134.6 nM, respectively) for both AT 1 WT and Q257A mutant-transfected cells. EXP3174 produced the largest rightward shift in the mutant.
Molecular Model of the Candesartan-AT 1 Receptor Complex-A representation of the candesartan-AT 1 receptor complex is shown in Fig. 6A . The free energy of binding was Ϫ92 kcal/mol for the WT-candesartan complex. The free energies were Ϫ5 to Ϫ13 kcal/mol for the Q257A-candesartan, the Q257A-EXP3174, and the WT-losartan complexes, suggesting that the binding free energies for antagonist-receptor complexes in the surmountable state are nearly comparable with each other and significantly differ from the complex in the insurmountable state. The final internal energy of the ligands were Ϫ0.49 to ϩ0.47 kcal/mol, implying that the conformation of the ligands are not strained. With this model we aimed to investigate the relationships between the three residues, Lys 199 , His 256 , and Gln 257 , which were experimentally determined to contribute to the effects of insurmountable antago- nists. The relative positions of these three residues in threedimensional space is elucidated (Fig. 6B) .
In this conformation the distance between and ␣-COO Ϫ of candesartan was 4.98 Å, and the distance between Ala 257 and ␣-COO Ϫ of candesartan was 8.18 Å. The distances between the tetrazole group of candesartan and the side chains of Lys 199 and His 256 were determined to range from 2.51 to 7.31 Å (Fig.  6B) . In addition several neighboring aromatic and hydrophobic side chains contribute to a cluster of interactions with the biphenyl core. In the absence of candesartan, the Lys 199 , His 256 , and Gln 257 were 3-6 Å apart, allowing them to be involved in a network of weak interactions.
DISCUSSION
The most important result of this study is the finding that the Q257A mutation renders the AT 1 receptor insensitive to insurmountable antagonism by EXP3174 and candesartan. Preincubation of these insurmountable antagonists with the WT receptor leads to apparent increase of binding affinity and suppression of the Ang II-induced maximal IP response. Both of these effects exerted by EXP3174 were nearly completely abolished, and the effects exerted by candesartan were suppressed in the Q257A mutant (as seen in Figs. 2-4) . It is important to note that the classical antagonist and inverseagonist activities of EXP3174, candesartan, and losartan were not affected (as seen in Fig. 5 ) by the Q257A mutation. Thus, display of insurmountable antagonism appears to specifically require the Gln 257 side chain in the WT AT 1 receptor and the ␣-carboxyl group in candesartan and EXP3174 (Fig. 1) . Interaction between them appears to be a hydrogen bonding since substitution with potentially negative-charged Glu side chain did not cause a greater defect than substitution with Ala, implying that the carboxyl group of the substituted Glu may be protonated, allowing it to form a hydrogen bond with EXP3174 and candesartan. This unique property was not observed in several other AT 1 receptor mutants of residues that were considered candidates (Fig. 1) to interact with this ␣-carboxyl group of the insurmountable antagonists based on a molecular model (Fig. 6) . Preincubation of each mutant receptor with candesartan and EXP3174 led to increases of affinity as in the WT (Table I) . Previously, Fierens et al. (11) reported that a K199Q mutation was more detrimental for the binding of the insurmountable antagonists than the binding of surmountable antagonists, and Schambye et al. (12) report that a N295A mutation selectively reduced the affinity of insurmountable antagonists. Although the substitution of Lys 199 decreased the affinity for candesartan more than losartan, this effect was not selective since the EXP3174 binding was not effected in a similar way (see Table I ). The K199Q/H256A double mutant decreased the affinity for all three antagonists, implying that the His 256 side chain compensates the effect of Lys 199 mutation to varying degrees. This observation is consistent with a previous report from this laboratory (6) were proposed to interact with the tetrazole group that is common to all three antagonists. Substitution of Asn 295 with Ala on the other hand decreased affinity for all ligands including Ang II and losartan, suggesting that Asn 295 interaction is not specific for insurmountable antagonists. Instead, mutation of this residue likely affects general conformation of the TM domain, accounting for loss of affinity for all ligands. Based on these observations we conclude that hydrogen bonding with the Gln 257 side chain is the molecular basis for insurmountable behavior of EXP3174.
A residual insurmountable effect of candesartan on the Q257A mutant (2-fold increase in affinity for this mutant compared with 10-fold in WT in preincubation experiment) is likely due to the interaction of its ethoxy group with an unknown site on the AT 1 receptor, which distinguishes it from EXP3174. Thus, additive-bonding interactions may account for different insurmountable efficacy of AT 1 antagonists reported (2) (3) (4) (5) (Fig. 2B) . Thus, insurmountable binding can change to surmountable binding from not achieving the critical Gln 257 antagonist contact due to additive entropy effects of multiple mutations.
On the basis of the finding that the insurmountable antagonists behave like surmountable antagonists with the Q257A mutation, we propose that in the WT receptor an antagonistmediated conformational transition is responsible for both slow dissociation and inhibition of maximal IP response. In the past both equilibrium and kinetic models of insurmountable antagonism of the AT 1 receptor have argued that the resulting "hemi-equilibrium" pattern of the diminished functional response (see Fig. 4 ) would be dependent on the antagonist dis- sociation rate (2) (3) (4) (5) . The magnitude of the response to agonist will depend on the rate and the degree of activation. This implies that the maximum response to Ang II after preincubation with an insurmountable antagonist can be recovered simply by increasing the contact time of Ang II. But under our experimental conditions, i.e. 45 min of exposure of up to 10,000-fold molar excess of Ang II did not restore the response of WT inhibited by candesartan and EXP3174 (Fig. 4) . Our findings are consistent with previous reports in both aortic contraction assays and transfected cells in which time for resensitization to Ang II was estimated to be Ͼ2 h. The reduced dissociation and association rate constants in the Q257A mutant suggest that this mutation affects formation of the slow-dissociating insurmountable antagonist-receptor complex. The barrier for dissociation of EXP3174 and candesartan in the WT receptor is gained by their specific interaction with the Gln 257 side chain. An alternative explanation could be that the "slow-dissociating" antagonist-receptor complexes are in a different subcellular location. The peptide antagonists of the AT 1 receptor are capable of inducing AT 1 receptor internalization (13); therefore, the possibility of candesartan-induced internalization was previously suggested (14) . Partitioning of antagonist-AT 1 receptor complex into an acid-resistant subcellular compartment was reported (15) . But in internalization-defective AT 1 mutant the candesartan receptor complex was still found to be acidresistant (16) . Direct internalization measurements with enhanced green fluorescent protein-tagged AT 1 receptor treated with losartan or candesartan suggest the absence of internalization to intracellular vesicular compartments (17, 18) . These findings suggest that insurmountable antagonists are unlikely to promote internalization similar to that induced by peptide antagonists and agonists. Either the mild acid treatment was insufficient to discriminate between surface bound and a novel form of antagonist-receptor complex or acid resistance is a conformational state of the candesartan-bound AT 1 receptor in the plasma membrane. An insurmountable antagonist-induced conformation change is necessary to consider either of these explanations. The evidence presented here suggests that the Q257A mutation must affect this step in the AT 1 receptor.
Insurmountable Antagonist Versus Inverse Agonist-With respect to the potential involvement of Gln 257 bonding with candesartan or EXP3174 in inverse agonist properties of these compounds, data presented in Fig. 5 suggest that the molecular basis of insurmountable antagonist and inverse agonist phenomenon are different. We conclude that the Gln 257 -candesartan (EXP3174) bond is not directly involved in mediating the conformation that results in the inactivation of the AT 1 receptor function. The bond sustains the receptor in the inactive conformation and prevents access to agonist. For both basic pharmacology and drug design it is important to understand this distinction in mechanisms whereby drugs achieve distinct effects. It has been assumed that these drugs achieved their effects by stabilizing an inactive state of the receptor at the expense of partially (RЈ)-or fully (R*)-activated states (19, 20) . We suggest that the insurmountable AT 1 receptor antagonists reveal an additional step that should be considered in the models of antagonism of GPCRs. Thus, in addition to becoming an important therapeutic class of drugs, the AT 1 receptor antagonists are exciting from a receptor theory viewpoint as well.
Model and General Implications-Mechanisms of how the binding of agonists and inverse agonists preferentially stabilize, respectively, the active and inactive conformations of GPCRs requires better understanding at a molecular level. The current view is that GPCRs exist in a dynamic equilibrium between active (R*) and inactive states governed by an allosteric constant (R*), and the efficacy of a ligand is a function of its relative affinity for R and R* states. Classical antagonists, also called neutral antagonists, have equal affinity for both receptor states, inverse agonists preferentially bind to R, thereby shifting the position of equilibrium toward the inactive state, and the agonists preferentially bind to R*. There is rapid progress in understanding the molecular mechanisms of agonist-mediated activation, but the mechanisms by which the inactive state(s) of the receptor is generated by inverse agonist binding remain unclear. The Gln 257 mutations reported in this study shed new light on this issue.
The prototypical GPCR, mammalian rhodopsin, exists in at least three different states, the silent "ground" state (Rg) is stabilized by the inverse agonist, 11-cis-retinal; the low activity state is the retinal-free opsin; and the fully active state (R*) is all-trans-retinal bound metarhodopsin II (20 -22) . Stabilization of the Rg state by the 11-cis-retinal lowers the activity 6 -10 times, which enables rhodopsin to operate as a single photon detector even in the presence of high levels of activated rhodopsin in rod cells (22) . The 11-cis-retinal should be considered an insurmountable antagonist in addition to inverse agonist of opsin since the K d of the 11-cis-retinal complex with opsin is Ͼ150 h in the dark. The stability of the Rg state of opsin is due to a covalent protonated Schiff base linkage with Lys 296 in the center of the TM domain, which is stabilized by the Glu 113 counter ion and a network of hydrogen bonds. As to the ligandreceptor interactions in other GPCRs, the antagonists, full or partial agonists were found to mediate different conformational changes in the ␤ 2 -adrenoreceptor (23, 24) . Therefore, it seems likely that different activity states are a heterogeneous population of receptor conformations. How the stability of new states in GPCRs is achieved in the face of interaction of different types of ligands is not clear. Neighborhood and environment effects on broad ensembles of microscopic conformations of GPCRs need to be better understood.
Our observations with the Gln 257 mutants of the AT 1 receptor, which completely blocked insurmountable antagonist activity while maintaining specific binding, the inverse agonist effects, and the agonist-mediated transition to the R* conformation, suggest that an "inactive state" comparable but not identical to the Rg state of opsin should be considered. It is now well established that activation of GPCRs involves disruption of a network of intramolecular interactions leading to separation of TM-III and TM-VI helices (20) . Disruption of a network of interactions that stabilize the receptors in inactive conformations constitutes the receptor activation switch. The precise residues involved in these interactions may vary between different receptors (20) . The data presented in this study suggest that a different network of intramolecular interactions in the AT 1 receptor underlies the actions of insurmountable antagonists. The structural model of the AT 1 receptor, presented in Fig. 6,  2 indicates that the side chains of residues Lys 199 , His 256 , and Gln 257 are 3-6 Å apart, and the aromatic cluster formed between the side chains of Phe 259 and Trp 253 , features conserved in other GPCRs, also constitute a constraining network. Stabilization of the biphenylimidazole antagonist-bound Rg state likely involves this network. We propose that AT 1 receptor insurmountable antagonist binding requires "leaning" on the Gln 257 residue in addition to the interaction of core structure of antagonists with the above-mentioned network. The leaning ability conferred by the presence of the ␣-carboxyl group in EXP3174 and Candesatran is the key for functional specialties (i.e. insurmountable antagonism in this case) of pharmacological derivatives and some times drug metabolites (i.e. EXP3174 is a metabolite of losartan) (25) . It is worth 2 C. Gogonea and S. Karnik, unpublished. noting here that leaning behavior of compounds could explain accidental antagonist to agonist transformation during systematic drug development efforts. Indeed, a subset of substituted biphenylimidazole derivatives (e.g. L-162,313) was found to possess agonist properties at the AT 1 receptor (26) . Further studies may reveal the existence of constraining networks and leaning behavior in other GPCR antagonists. Elucidation of such networks could provide a better understanding of the effects of insurmountable antagonists, inverse agonists, and antagonists on the conversion between different conformations of the GPCR structure.
